Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
11:35am, Friday, 26'th Sep 2025
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:01am, Friday, 26'th Sep 2025
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
3 Strong-Buy Dividend Growth Stocks
09:56am, Friday, 26'th Sep 2025
When it comes to investing, I am a big believer in the power of compounding dividends. I focus less on yield and more on dividend growth when analyzing dividend stocks.
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
08:30am, Friday, 26'th Sep 2025
New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines Gateway Labs model provides flexible lab space and tailored scientific engagement to sup
Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.
08:15am, Friday, 26'th Sep 2025
Trump's threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announ
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amy
US FDA approves Eli Lilly's therapy for metastatic breast cancer
02:18pm, Thursday, 25'th Sep 2025
Eli Lilly said on Thursday that the U.S. Food and Drug Administration has approved its therapy for the treatment of metastatic breast cancer in patients whose disease progressed after at least one lin
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
02:01pm, Thursday, 25'th Sep 2025
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monother
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
11:27am, Thursday, 25'th Sep 2025
Eli Lilly and Company (NYSE:LLY ) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of In
Eli Lilly halts trial of experimental weight-loss drug
06:47am, Thursday, 25'th Sep 2025
Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clin
Lilly plans to launch its experimental weight-loss pill in India, exec says
01:12am, Thursday, 25'th Sep 2025
Eli Lilly plans to bring its experimental oral weight-loss drug orforpligron in India as it sees scope for such products in the world's most populous nation, a senior executive said on Thursday.
Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?
04:44pm, Wednesday, 24'th Sep 2025
Eli Lilly (LLY -0.59%) is a pharmaceutical manufacturer, not a construction business. And yet construction has been a focal point of late, given that it's planning a set of new factories.
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
01:25pm, Wednesday, 24'th Sep 2025
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
The Big 3: AVGO, LLY, GS
12:30pm, Wednesday, 24'th Sep 2025
@Theotrade's Don Kaufman is back on Big 3 — and is bearish on all of today's stocks. He points to exuberant A.I.
2 stocks to reach $1 trillion market cap in 2026
10:47am, Wednesday, 24'th Sep 2025
Amid the ongoing United States stock market rally, several equities have experienced increased buying pressure, pushing their valuations closer to the coveted $1 trillion market capitalization mark.
